Monoclonal Antibodies: A Promising Treatment for Lymphoma

The video discusses a trial for a new lymphoma treatment using Madthera, a monoclonal antibody. This drug targets and attacks cancer cells by binding to CD20 proteins on their surface. The treatment is administered weekly over four weeks, with the first session requiring hospital observation. Madthera's mechanism involves targeting CD20 proteins found on pre B&B lymphocytes, leading to the death of tumor cells.

What specific proteins do Med Thera target in lymphoma treatment?

What is the outcome of the binding of Med Thera to CD20 proteins?